CA2948013A1 - Anticorps reagissant avec un epitope situe dans la region n-terminale de muc5ac comprenant un sous-domaine 2 riche en cysteine (cys2) - Google Patents
Anticorps reagissant avec un epitope situe dans la region n-terminale de muc5ac comprenant un sous-domaine 2 riche en cysteine (cys2) Download PDFInfo
- Publication number
- CA2948013A1 CA2948013A1 CA2948013A CA2948013A CA2948013A1 CA 2948013 A1 CA2948013 A1 CA 2948013A1 CA 2948013 A CA2948013 A CA 2948013A CA 2948013 A CA2948013 A CA 2948013A CA 2948013 A1 CA2948013 A1 CA 2948013A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- seq
- muc5ac
- antibodies
- pancreatic cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4725—Mucins, e.g. human intestinal mucin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018989P | 2014-06-30 | 2014-06-30 | |
| US62/018,989 | 2014-06-30 | ||
| US201462091932P | 2014-12-15 | 2014-12-15 | |
| US62/091,932 | 2014-12-15 | ||
| US14/632,480 | 2015-02-26 | ||
| US14/632,480 US9238084B2 (en) | 2003-06-16 | 2015-02-26 | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
| US201562148428P | 2015-04-16 | 2015-04-16 | |
| US62/148,428 | 2015-04-16 | ||
| PCT/US2015/038252 WO2016003869A1 (fr) | 2014-06-30 | 2015-06-29 | Anticorps réagissant avec un épitope situé dans la région n-terminale de muc5ac comprenant un sous-domaine 2 riche en cystéine (cys2) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2948013A1 true CA2948013A1 (fr) | 2016-01-07 |
Family
ID=55019867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2948013A Abandoned CA2948013A1 (fr) | 2014-06-30 | 2015-06-29 | Anticorps reagissant avec un epitope situe dans la region n-terminale de muc5ac comprenant un sous-domaine 2 riche en cysteine (cys2) |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3160499A4 (fr) |
| CA (1) | CA2948013A1 (fr) |
| WO (1) | WO2016003869A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4328244A4 (fr) * | 2021-04-21 | 2026-04-01 | Nihon Mediphysics Co Ltd | Anticorps humanisé marqué par un nucléide émettant un rayonnement ? |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20190622A1 (es) | 2016-06-02 | 2019-04-26 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo |
| MA49796A (fr) | 2017-12-01 | 2020-06-03 | Abbvie Inc | Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci |
| AU2020366846A1 (en) * | 2019-10-18 | 2022-05-26 | Nihon Medi-Physics Co., Ltd. | Humanized antibody and method for using the same |
| EP4049684A4 (fr) | 2019-10-18 | 2023-10-25 | Nihon Medi-Physics Co., Ltd | Anticorps humanisé marqué par ri |
| KR20240014067A (ko) | 2021-05-28 | 2024-01-31 | 애로우헤드 파마슈티컬스 인코포레이티드 | 뮤신 5AC (MUC5AC)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법 |
| EP4408468A4 (fr) * | 2021-09-28 | 2025-07-02 | Frontaim Biomedicines Inc | Formats multiples de complexes moléculaires |
| CN114276980B (zh) * | 2021-12-29 | 2023-12-05 | 王意忠 | 一种培养适合临床应用的胰岛细胞的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8491896B2 (en) * | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| US8574854B2 (en) * | 2002-06-14 | 2013-11-05 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
| US8821868B2 (en) * | 2002-06-14 | 2014-09-02 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| EP2331134A4 (fr) * | 2008-08-08 | 2014-10-15 | Immunomedics Inc | Anticorps anti-cancer pancréatique |
| CA2787753A1 (fr) * | 2010-01-22 | 2011-07-28 | Immunomedics, Inc. | Detection d'un adenocarcinome pancreatique a un stade precoce |
| WO2012040617A2 (fr) * | 2010-09-23 | 2012-03-29 | Neogenix Oncology, Inc. | Peptidomimétiques du cancer du côlon et du pancréas |
| AU2013360335B2 (en) * | 2012-12-13 | 2017-12-07 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| WO2014165506A1 (fr) * | 2013-04-01 | 2014-10-09 | Immunomedics, Inc. | Anticorps anti-mucines permettant la détection précoce et le traitement du cancer du pancréas |
-
2015
- 2015-06-29 WO PCT/US2015/038252 patent/WO2016003869A1/fr not_active Ceased
- 2015-06-29 EP EP15815785.9A patent/EP3160499A4/fr not_active Withdrawn
- 2015-06-29 CA CA2948013A patent/CA2948013A1/fr not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4328244A4 (fr) * | 2021-04-21 | 2026-04-01 | Nihon Mediphysics Co Ltd | Anticorps humanisé marqué par un nucléide émettant un rayonnement ? |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3160499A1 (fr) | 2017-05-03 |
| WO2016003869A1 (fr) | 2016-01-07 |
| EP3160499A4 (fr) | 2018-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9238084B2 (en) | Anti-mucin antibodies for early detection and treatment of pancreatic cancer | |
| US9452228B2 (en) | Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2) | |
| US9089618B2 (en) | Anti-mucin antibodies for early detection and treatment of pancreatic cancer | |
| CA2782194C (fr) | Combinaison d'anticorps radio-marquees et de conjugues anticorps-medicament pour le traitement du cancer pancreatique | |
| US8491896B2 (en) | Anti-pancreatic cancer antibodies | |
| CA2731438C (fr) | Anticorps anti-cancer pancreatique | |
| CA2899811A1 (fr) | Anticorps anti-mucines permettant la detection precoce et le traitement du cancer du pancreas | |
| US9513293B2 (en) | Detection of early-stage pancreatic adenocarcinoma | |
| WO2016003869A1 (fr) | Anticorps réagissant avec un épitope situé dans la région n-terminale de muc5ac comprenant un sous-domaine 2 riche en cystéine (cys2) | |
| US8974784B2 (en) | Anti-pancreatic cancer antibodies | |
| US20170137534A1 (en) | Anti-Pancreatic Cancer Antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20190702 |